In a MajesTEC-3 subgroup analysis, Tec-Dara showed 77% 3-year PFS vs 0% with standard therapy in functional high-risk R/R MM.
Rahul Banerjee, MD
Advertisement
Rahul Banerjee, MD, is an assistant professor at the Fred Hutchinson Cancer Center.
Articles by Rahul Banerjee, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
5 FAQs: Ebola Outbreaks and the Challenge of Public Trust
2
Incretin Innovation, Metabolic Liver Disease, and Cardiovascular Risk Reduction Dominate ADA 2026
3
Myeloma Experience Paves the Way for MRD in Trial Design and Regulatory Approval
4
Health Equity & Access Weekly Roundup: June 12, 2026
5